Compare Ryanair Holdings plc (RYAAY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs Zimmer Biomet Holdings Inc — how do they compare? Ryanair Holdings plc trades at $53.09 (market cap $27.11B), while Zimmer Biomet Holdings Inc trades at $88.93 (market cap $16.95B). The key difference: Ryanair Holdings plc is the larger of the two by market cap, and Ryanair Holdings plc pays the higher dividend (1.66%). Which is the better fit depends on your goals — on Pluang, investors hold Ryanair Holdings plc for 72 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| RYAAY | ZBH | |
|---|---|---|
Market Cap | $27.11B | $16.95B |
Volume | 2,427,380 | 2,505,240 |
Sector | Industrials | Health |
52-Week High | $73.82 | $103.98 |
52-Week Low | $51.95 | $79.58 |
Typical Hold Time | 72 Days | 89 Days |
Enterprise Value | $24.18B | $24.02B |
Dividend Yield | 1.66% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $53.1, down 5.18% on the day, reflecting a bearish technical signal amid mixed earnings performance. The company maintains strong profitability with a 12.13% net income margin and 22.41% ROE, while valuation metrics like a P/E of 13.43 appear attractive. Recent news highlights CEO commentary on Boeing MAX 10 certification delays and concerns over rising fuel costs impacting future airfares.
The stock presents a value opportunity given its low valuation multiples and robust cash flow generation, but faces near-term headwinds from volatile fuel prices and a lowered FY27 traffic outlook. Analyst consensus remains moderately bullish, though technical indicators suggest caution. Key risks include oil price sensitivity and competitive pressures in the European airline sector.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
